{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:01:23Z","timestamp":1782950483006,"version":"3.54.5"},"reference-count":161,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Vertigo in children is a challenging topic. The lack of dedicated trials, guidelines and papers causes inhomogeneity in the treatment of vertigo in children. Meniere\u2019s disease, migraine equivalents, vestibular neuritis, paroxysmal positional benign vertigo (BPPV), persistent postural-perceptual dizziness (PPPD) and motion sickness may affect children with various degrees of incidence and clinical severity compared to adults. Several drugs are proposed for the management of these conditions, even if their use is subordinated to the child\u2019s age. In this review, we summarize the existing evidence related to the use of drugs for this clinical condition in children as a start point for new trials, stating the urgent need for international guidelines.<\/jats:p>","DOI":"10.3390\/children9050584","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T01:55:51Z","timestamp":1650506151000},"page":"584","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The Pharmacological Treatment of Pediatric Vertigo"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2352-1146","authenticated-orcid":false,"given":"Pasquale","family":"Viola","sequence":"first","affiliation":[{"name":"Unit of Audiology, Regional Centre of Cochlear Implants and ENT Diseases, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1478-9551","authenticated-orcid":false,"given":"Gianmarco","family":"Marcian\u00f2","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacovigilance Unit, Department of Health Science, School of Medicine, University of Catanzaro, Mater Domini Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2294-0768","authenticated-orcid":false,"given":"Alessandro","family":"Casarella","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacovigilance Unit, Department of Health Science, School of Medicine, University of Catanzaro, Mater Domini Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7486-0140","authenticated-orcid":false,"given":"Davide","family":"Pisani","sequence":"additional","affiliation":[{"name":"Unit of Audiology, Regional Centre of Cochlear Implants and ENT Diseases, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Astorina","sequence":"additional","affiliation":[{"name":"Unit of Audiology, Regional Centre of Cochlear Implants and ENT Diseases, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Scarpa","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Salerno, 84081 Baronissi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Siccardi","sequence":"additional","affiliation":[{"name":"ENT Unit, Maria Vittoria Hospital, 10144 Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Basile","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacovigilance Unit, Department of Health Science, School of Medicine, University of Catanzaro, Mater Domini Hospital, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-6579","authenticated-orcid":false,"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacovigilance Unit, Department of Health Science, School of Medicine, University of Catanzaro, Mater Domini Hospital, 88100 Catanzaro, Italy"},{"name":"Research Center FAS@UMG, Department of Health Science, Magna Graecia University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-7902","authenticated-orcid":false,"given":"Luca","family":"Gallelli","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacovigilance Unit, Department of Health Science, School of Medicine, University of Catanzaro, Mater Domini Hospital, 88100 Catanzaro, Italy"},{"name":"Research Center FAS@UMG, Department of Health Science, Magna Graecia University, 88100 Catanzaro, Italy"},{"name":"Medifarmagen SRL, Department of Health Science, Magna Graecia University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9829-2229","authenticated-orcid":false,"given":"Giuseppe","family":"Chiarella","sequence":"additional","affiliation":[{"name":"Unit of Audiology, Regional Centre of Cochlear Implants and ENT Diseases, Department of Experimental and Clinical Medicine, Magna Graecia University, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/VES-2009-0343","article-title":"Classification of vestibular symptoms: Towards an international classification of vestibular disorders","volume":"19","author":"Bisdorff","year":"2009","journal-title":"J. Vestib. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.otc.2018.03.003","article-title":"Vertigo and Dizziness: Understanding and Managing Fall Risk","volume":"51","author":"Alyono","year":"2018","journal-title":"Otolaryngol. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/MAO.0b013e3181f20673","article-title":"Prevalence of vestibular and balance disorders in children","volume":"31","author":"Morlet","year":"2010","journal-title":"Otol. Neurotol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jpeds.2015.12.002","article-title":"Epidemiology of Dizziness and Balance Problems in Children in the United States: A Population-Based Study","volume":"171","author":"Li","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijporl.2014.02.009","article-title":"Prevalence and diagnosis of vestibular disorders in children: A review","volume":"78","author":"Gioacchini","year":"2014","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_6","first-page":"1027","article-title":"The Challenge of Pediatric Vertigo","volume":"2","author":"Chiarella","year":"2017","journal-title":"J. Ear. Nose Throat Disord"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrneurol.2017.58","article-title":"The dizzy patient: Don\u2019t forget disorders of the central vestibular system","volume":"13","author":"Brandt","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"ref_8","first-page":"578","article-title":"Vestibular disorders in children","volume":"47","year":"2009","journal-title":"Int. J. Audiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1055\/s-0029-1241043","article-title":"Vertigo: Epidemiologic Aspects","volume":"29","author":"Neuhauser","year":"2009","journal-title":"Semin. Neurol."},{"key":"ref_10","first-page":"61","article-title":"Vestibular Migraine of Childhood and Recurrent Vertigo of Childhood: Diagnostic criteria Consensus document of the Committee for the Classification of Vestibular Disorders of the B\u00e1r\u00e1ny Society and the International Headache Society","volume":"31","author":"Widdershoven","year":"2021","journal-title":"J. Vestib. Res. Equilib. Orientat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1046\/j.1468-2982.1995.1501022.x","article-title":"Paroxysmal vertigo as a migraine equivalent in children: A population-based study","volume":"15","author":"Russell","year":"1995","journal-title":"Cephalalgia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/brain\/87.1.141","article-title":"Benign paroxysmal vertigo of childhood: A variety of vestibular neuronitis","volume":"87","author":"Basser","year":"1964","journal-title":"Brain"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3233\/VES-2012-0453","article-title":"Vestibular migraine: Diagnostic criteria","volume":"22","author":"Lempert","year":"2012","journal-title":"J. Vestib. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00415-015-7905-2","article-title":"Vestibular migraine: The most frequent entity of episodic vertigo","volume":"263","author":"Dieterich","year":"2016","journal-title":"J. Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1468-2982.2004.00662.x","article-title":"Vertigo and dizziness related to migraine: A diagnostic challenge","volume":"24","author":"Neuhauser","year":"2004","journal-title":"Cephalalgia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd ed","volume":"38","author":"Olesen","year":"2018","journal-title":"Cephalalgia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1177\/0333102411405228","article-title":"Vestibular migraine-validity of clinical diagnostic criteria","volume":"31","author":"Radtke","year":"2011","journal-title":"Cephalalgia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ejpn.2018.03.008","article-title":"Benign paroxysmal migraine variants of infancy and childhood: Transitions and clinical features","volume":"22","author":"Brodsky","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ejpn.2013.01.006","article-title":"Is benign paroxysmal vertigo of childhood a migraine precursor?","volume":"17","author":"Marcos","year":"2013","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/1756285611401647","article-title":"Management of vestibular migraine","volume":"4","author":"Bisdorff","year":"2011","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11916-016-0600-x","article-title":"Vestibular Migraine in Children and Adolescents","volume":"20","author":"Langhagen","year":"2016","journal-title":"Curr. Pain. Headache Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejpn.2015.09.011","article-title":"Evaluation and management of vestibular migraine in children: Experience from a pediatric vestibular clinic","volume":"20","author":"Brodsky","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1371\/journal.pmed.0050166","article-title":"Greater Response to Placebo in Children Than in Adults: A Systematic Review and Meta-Analysis in Drug-Resistant Partial Epilepsy","volume":"5","author":"Rheims","year":"2008","journal-title":"PLoS Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/pr.2016.181","article-title":"Is the perceived placebo effect comparable between adults and children? A meta-regression analysis","volume":"81","author":"Janiaud","year":"2017","journal-title":"Pediatr. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jpeds.2014.06.040","article-title":"Harnessing the placebo effect in pediatric migraine clinic","volume":"165","author":"Faria","year":"2014","journal-title":"J. Pediatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11916-013-0339-6","article-title":"Migraine-related symptoms in childhood topical collection on childhood and adolescent headache","volume":"17","author":"Winner","year":"2013","journal-title":"Curr. Pain Headache Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1055\/s-0031-1283158","article-title":"Vertigo and dizziness in childhood update on diagnosis and treatment","volume":"42","author":"Jahn","year":"2011","journal-title":"Neuropediatrics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1526-4610.2007.00728.x","article-title":"Levetiracetam prophylaxis in pediatric migraine\u2014An open-label study","volume":"47","author":"Pakalnis","year":"2007","journal-title":"Headache"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/0333102419851814","article-title":"Levetiracetam for prophylactic treatment of pediatric migraine: A randomized double-blind placebo-controlled trial","volume":"39","author":"Montazerlotfelahi","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40272-015-0125-5","article-title":"Prophylaxis of Migraine in Children and Adolescents","volume":"17","author":"Kacperski","year":"2015","journal-title":"Pediatr. Drugs"},{"key":"ref_31","unstructured":"(2022, February 12). NIH National Institutes of Health Topiramate-Label, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=21628112-0c47-11df-95b3-498d55d89593."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1177\/0333102419888485","article-title":"Cinnarizine and sodium valproate as the preventive agents of pediatric migraine: A randomized double-blind placebo-controlled trial","volume":"40","author":"Amanat","year":"2020","journal-title":"Cephalalgia"},{"key":"ref_33","unstructured":"(2022, February 12). NIH National Institutes of Health Amitriptyline Hydrochloride Tablet, Coated-Label, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a4d012a4-cd95-46c6-a6b7-b15d6fd5269d."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ardp.19963290206","article-title":"Synthesis and pharmacology of combined histamine H1-\/H2-receptor antagonists containing diphenhydramine and cyproheptadine derivatives","volume":"329","author":"Wolf","year":"1996","journal-title":"Arch. Pharm."},{"key":"ref_35","unstructured":"AIFA (2016). Riassunto Delle Caratteristiche del Prodotto-Ciproeptadina, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/MAO.0000000000001628","article-title":"Effect of Prophylactic Medication on Associated Dizziness and Motion Sickness in Migraine","volume":"39","author":"Lee","year":"2018","journal-title":"Otol. Neurotol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00003495-198938040-00002","article-title":"Flunarizine: A Reappraisal of its Pharmacological Properties and Therapeutic Use in Neurological Disorders","volume":"38","author":"Todd","year":"1989","journal-title":"Drugs"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1468-2982.1988.0801001.x","article-title":"Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study","volume":"8","author":"Sorge","year":"1988","journal-title":"Cephalalgia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejpn.2005.05.004","article-title":"Sodium Valproate versus Propranolol in paediatric migraine prophylaxis","volume":"9","author":"Ashrafi","year":"2005","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2165\/11316270-000000000-00000","article-title":"A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients","volume":"12","author":"Bidabadi","year":"2010","journal-title":"Pediatr. Drugs"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/j.1526-4610.2008.01138.x","article-title":"Efficacy and tolerability of almotriptan in adolescents: A randomized, double-blind, placebo-controlled trial","volume":"48","author":"Linder","year":"2008","journal-title":"Headache"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1177\/0333102412451358","article-title":"Efficacy and tolerability of rizatriptan in pediatric migraineurs: Results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design","volume":"32","author":"Ho","year":"2012","journal-title":"Cephalalgia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/01.wnl.0000238179.79888.44","article-title":"A randomized trial of rizatriptan in migraine attacks in children","volume":"67","author":"Ahonen","year":"2006","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1212\/01.wnl.0000231138.18629.d5","article-title":"Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen","volume":"67","author":"Evers","year":"2006","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1111\/head.12859","article-title":"Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ)","volume":"56","author":"Winner","year":"2016","journal-title":"Headache"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1526-4610.2007.00652.x","article-title":"Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine","volume":"47","author":"Hershey","year":"2007","journal-title":"Headache"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1212\/01.wnl.0000172339.15577.a6","article-title":"Effect of tryptophan depletion on symptoms of motion sickness in migraineurs","volume":"65","author":"Drummond","year":"2005","journal-title":"Neurology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1468-2982.2006.01212.x","article-title":"Tryptophan depletion increases nausea, headache and photophobia in migraine sufferers","volume":"26","author":"Drummond","year":"2006","journal-title":"Cephalalgia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/jmf.2014.0113","article-title":"A Medical Food Formulation of Griffonia simplicifolia\/Magnesium for Childhood Periodic Syndrome Therapy: An Open-Label Study on Motion Sickness","volume":"18","author":"Esposito","year":"2015","journal-title":"J. Med. Food"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Jahn, K. (2016). Vertigo and Dizziness in Children, Elsevier B.V.. [1st ed.].","DOI":"10.1016\/B978-0-444-63437-5.00025-X"},{"key":"ref_51","unstructured":"(2021, September 04). NIH National Institutes of Health Metoprolol Succinate Capsule, Extended Release-Label, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=90aa06a3-100f-4466-b950-506303707b01#section-8.4."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Fancello, V., Palma, S., Monzani, D., Pelucchi, S., Genovese, E., and Ciorba, A. (2021). Vertigo and Dizziness in children: An Update. Children, 8.","DOI":"10.3390\/children8111025"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1055\/s-0029-1241040","article-title":"Vestibular neuritis","volume":"29","author":"Strupp","year":"2009","journal-title":"Semin. Neurol."},{"key":"ref_54","unstructured":"Mora, E. (2005, January 23\u201325). Clinica delle labirintopatie periferiche. Proceedings of the Societ\u00e0 Italiana di Otorinolaringologia e Chirurgia Cervico\u2014Facciale, Roma, Italy."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0040-1717067","article-title":"Vestibular Neuritis in Patients among Different Age Groups: Clinical Features and Outcomes","volume":"31","author":"Yan","year":"2020","journal-title":"J. Am. Acad. Audiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijporl.2016.01.027","article-title":"Vestibular neuritis in children and adolescents: Clinical features and recovery","volume":"83","author":"Brodsky","year":"2016","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_57","first-page":"1","article-title":"Corticosteroids for the treatment of idiopathic acute vestibular dysfunction (vestibular neuritis)","volume":"5","author":"Fishman","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijporl.2018.05.028","article-title":"Vertigo in children; a narrative review of the various causes and their management","volume":"111","author":"Devaraja","year":"2018","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MAO.0000000000001673","article-title":"Benign Paroxysmal Positional Vertigo (BPPV) in Children and Adolescents: Clinical Features and Response to Therapy in 110 Pediatric Patients","volume":"39","author":"Brodsky","year":"2018","journal-title":"Otol. Neurotol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Babu, S., Schutt, C.A., and Bojrab, D.I. (2019). Diagnosis and Treatment of Vestibular Disorders, Springer.","DOI":"10.1007\/978-3-319-97858-1"},{"key":"ref_61","first-page":"S1","article-title":"Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update)","volume":"156","author":"Bhattacharyya","year":"2017","journal-title":"Otolaryngol.\u2014Head Neck Surg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"110008","DOI":"10.1016\/j.ijporl.2020.110008","article-title":"How rare is benign paroxysmal positional vertigo in children? A review of 20 cases and their epidemiology","volume":"132","author":"Choi","year":"2020","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/PEP.0000000000000249","article-title":"Benign paroxysmal positional vertigo in 2 children: A case series","volume":"28","author":"Fay","year":"2016","journal-title":"Pediatr. Phys. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/JSM.0000000000000617","article-title":"Benign paroxysmal positional vertigo after pediatric sports-related concussion","volume":"30","author":"Reimer","year":"2020","journal-title":"Clin. J. Sport Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/audiolres11010006","article-title":"Benign positional paroxysmal vertigo in children","volume":"11","author":"Balzanelli","year":"2021","journal-title":"Audiol. Res."},{"key":"ref_66","first-page":"117","article-title":"Approach to residual dizziness after successfully treated benign paroxysmal positional vertigo: Effect of a polyphenol compound supplementation","volume":"11","author":"Casani","year":"2019","journal-title":"Clin. Pharmacol. Adv. Appl."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.pop.2013.10.004","article-title":"Dizziness and vertigo","volume":"41","author":"Wipperman","year":"2014","journal-title":"Prim. Care\u2014Clin. Off. Pract."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"102289","DOI":"10.1016\/j.amjoto.2019.102289","article-title":"Low-dose intratympanic gentamicin administration for unilateral Meniere\u2019s disease using a method based on clinical symptomatology: Preliminary results","volume":"40","author":"Scarpa","year":"2019","journal-title":"Am. J. Otolaryngol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00405-019-05682-4","article-title":"Food-induced stimulation of the antisecretory factor to improve symptoms in Meniere\u2019s disease: Our results","volume":"277","author":"Scarpa","year":"2020","journal-title":"Eur. Arch. Oto-Rhino-Laryngol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"102673","DOI":"10.1016\/j.amjoto.2020.102673","article-title":"The role of endogenous Antisecretory Factor (AF) in the treatment of M\u00e9ni\u00e8re\u2019s Disease: A two-year follow-up study. Preliminary results","volume":"41","author":"Viola","year":"2020","journal-title":"Am. J. Otolaryngol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.37825\/2239-9747.1009","article-title":"Pharmacological, surgical and diagnostic innovations in Meniere\u2019s disease: A review","volume":"23","author":"Scarpa","year":"2020","journal-title":"Transl. Med.@ UniSa"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102939","DOI":"10.1016\/j.amjoto.2021.102939","article-title":"Therapeutic options in Meniere\u2019s disease: Our experience","volume":"42","author":"Cassandro","year":"2021","journal-title":"Am. J. Otolaryngol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijporl.2017.11.029","article-title":"Pediatric Meniere\u2019s disease","volume":"105","author":"Wang","year":"2018","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/lary.1978.88.9.1504","article-title":"M\u00e9ni\u00e8re\u2019s disease in children","volume":"88","author":"Meyerhoff","year":"1978","journal-title":"Laryngoscope"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0165-5876(01)00576-6","article-title":"M\u00e9ni\u00e9re\u2019s disease in childhood","volume":"61","author":"Akagi","year":"2001","journal-title":"Int. J. Pediatr. Otorhinolaryngol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1017\/S0022215106000569","article-title":"Rare cases of M\u00e9ni\u00e8re\u2019s disease in children","volume":"120","author":"Choung","year":"2006","journal-title":"J. Laryngol. Otol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0196-0709(87)80001-7","article-title":"M\u00e9ni\u00e8re\u2019s disease in children","volume":"8","author":"Hausler","year":"1987","journal-title":"Am. J. Otolaryngol."},{"key":"ref_78","unstructured":"AIFA (2017). Riassunto Delle caratteristiche del Prodotto-Carvasin, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/00016489109131485","article-title":"Intratympanic gentamicin therapy for meniere\u2019s disease placed by a tubal catheter with systematic isosorbide","volume":"111","author":"Yamazaki","year":"1991","journal-title":"Acta Otolaryngol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000275597","article-title":"Treatment of M\u00e9ni\u00e8re\u2019s disease with isosorbide","volume":"44","author":"Kitahara","year":"1982","journal-title":"ORL J. Otorhinolaryngol. Relat. Spec."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S0022215100096523","article-title":"Juvenile Meniere\u2019 s disease","volume":"99","author":"Filipo","year":"1985","journal-title":"J. Laryngol. Otol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3109\/00016489.2011.643240","article-title":"M\u00e9niere\u2019s disease in children aged 4\u20137 years","volume":"132","author":"Brantberg","year":"2012","journal-title":"Acta Otolaryngol."},{"key":"ref_83","unstructured":"AIFA (2021). Riassunto Delle Caratteristiche del Prodotto-Idroclorotiazide, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11892-018-0976-6","article-title":"Type 2 Diabetes and Thiazide Diuretics","volume":"18","author":"Scheen","year":"2018","journal-title":"Curr. Diab. Rep."},{"key":"ref_85","unstructured":"Laurence Brunton, R.H.D. (2018). Goodman & Gillman\u2019s. The Pharmacological Basis of Therapy, McGraw-Hill. [13th ed.]."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jaad.2019.08.086","article-title":"Thiazides and nonmelanoma skin cancer: Is it a class effect?","volume":"82","author":"Humbert","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_87","unstructured":"(2022, March 01). National Institutes of Health Spironolactone-Label, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=fb66327e-8261-46ae-b39a-4fa79d520844#section-11.2."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1159\/000359963","article-title":"Antihistamines","volume":"100","author":"Church","year":"2014","journal-title":"Chem. Immunol. Allergy"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1523\/JNEUROSCI.1350-18.2018","article-title":"Histamine H1 receptor contributes to vestibular compensation","volume":"39","author":"Chen","year":"2019","journal-title":"J. Neurosci."},{"key":"ref_91","first-page":"S1","article-title":"Clinical Practice Guideline: M\u00e9ni\u00e8re\u2019s Disease","volume":"162","author":"Basura","year":"2020","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_92","unstructured":"AIFA (2021). Riassunto Delle Caratteristiche del Prodotto-Dimenidrinato, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_93","unstructured":"AIFA (2017). Fluxarten, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_94","unstructured":"AIFA (2016). Riassunto Delle Caratteristiche del Prodotto-Flunarizina, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/MAO.0b013e31826dba83","article-title":"Oral Steroid Treatment for Hearing Improvement in Meniere\u2019s Disease and Endolymphatic Hydrops","volume":"33","author":"Fisher","year":"2012","journal-title":"Otol. Neurotol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3233\/VES-170622","article-title":"Diagnostic criteria for persistent postural-perceptual dizziness (PPPD): Consensus document of the committee for the classification of vestibular disorders of the barany society","volume":"27","author":"Staab","year":"2017","journal-title":"J. Vestib. Res. Equilib. Orientat."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/MAO.0000000000003212","article-title":"Persistent Postural-Perceptual Dizziness in Children and Adolescents","volume":"42","author":"Wang","year":"2021","journal-title":"Otol. Neurotol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/wps.20765","article-title":"Safety of 80 antidepressants, antipsychotics, anti-attention-deficit\/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: A large scale systematic meta-review of 78 adverse effects","volume":"19","author":"Solmi","year":"2020","journal-title":"World Psychiatry"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/WCO.0000000000000163","article-title":"Pathophysiology and treatment of motion sickness","volume":"28","author":"Golding","year":"2015","journal-title":"Curr. Opin. Neurol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/014107687807101109","article-title":"Motion sickness adaptation: A neural mismatch model","volume":"71","author":"Reason","year":"1978","journal-title":"J. R. Soc. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00415-012-6685-1","article-title":"Down on heights? One in three has visual height intolerance","volume":"260","author":"Huppert","year":"2013","journal-title":"J. Neurol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00431-014-2351-1","article-title":"Motion sickness prevalence in school children","volume":"173","author":"Henriques","year":"2014","journal-title":"Eur. J. Pediatr."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejpn.2020.06.010","article-title":"Severe motion sickness in infants and children","volume":"28","author":"Lipson","year":"2020","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/bcp.14257","article-title":"The effects of meclizine on motion sickness revisited","volume":"86","author":"Wibble","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2466\/pms.1999.88.3.707","article-title":"Physiological and behavioral effects of an antivertigo antihistamine in adults","volume":"88","author":"Lauter","year":"1999","journal-title":"Percept. Mot. Skills"},{"key":"ref_106","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases (2012). Clinical and Research Information on Drug-Induced Liver Injury, National Institute of Diabetes and Digestive and Kidney Diseases. Meclizine."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/archneur.1972.00490140033006","article-title":"Meclizine and Placebo in Treating Vertigo of Vestibular Origin: Relative Efficacy in a Double-Blind Study","volume":"27","author":"Cohen","year":"1972","journal-title":"Arch. Neurol."},{"key":"ref_108","first-page":"216","article-title":"Clinical efficacy of Acetylleucine, meclizine and betahistine in dizziness: Systematic review and meta-analysis of randomised controlled trials","volume":"133","author":"Boussageon","year":"2017","journal-title":"Exerc. Rev. Francoph. Med. Gen."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1177\/0269881113516201","article-title":"Evaluation of the effects of anti-motion sickness drugs on subjective sleepiness and cognitive performance of healthy males","volume":"28","author":"Weerts","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/00002018-200831050-00002","article-title":"Drug-induced urinary retention: Incidence, management and prevention","volume":"31","author":"Verhamme","year":"2008","journal-title":"Drug Saf."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4103\/1119-3077.146969","article-title":"Drugs with anticholinergic side-effects in primary care","volume":"18","author":"Yayla","year":"2015","journal-title":"Niger. J. Clin. Pract."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Shinohara, M., Shinohara, M., Zhao, J., Fu, Y., Liu, C.C., Kanekiyo, T., and Bu, G. (2019). 5-HT3 antagonist ondansetron increases apoE secretion by modulating the LXR-ABCA1 pathway. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061488"},{"key":"ref_113","first-page":"19","article-title":"Experience with ondansetron in chemotherapy-and radiotherapy-induced emesis","volume":"6","author":"Dicato","year":"1992","journal-title":"Eur. J. Anaesthesiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jpsychires.2019.02.024","article-title":"Adjunctive ondansetron for schizophrenia: A systematic review and meta-analysis of randomized controlled trials","volume":"113","author":"Zheng","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/14740338.2019.1568988","article-title":"Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: A systematic review and meta-analysis","volume":"18","author":"Patel","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jemermed.2017.05.003","article-title":"Postoperative Anticholinergic Poisoning: Concealed Complications of a Commonly Used Medication","volume":"53","author":"Zhang","year":"2017","journal-title":"J. Emerg. Med."},{"key":"ref_117","unstructured":"Riad, M., and Hithe, C.C. (2022, March 01). Scopolamine, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554397\/."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jclinane.2011.07.019","article-title":"Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting","volume":"24","author":"Pergolizzi","year":"2012","journal-title":"J. Clin. Anesth."},{"key":"ref_119","first-page":"1011","article-title":"Transdermal scopolamine delivery system (TRANSDERM-V) and acute angle-closure glaucoma","volume":"15","author":"Hamill","year":"1983","journal-title":"Ann. Ophthalmol."},{"key":"ref_120","first-page":"CD002851","article-title":"Scopolamine (hyoscine) for preventing and treating motion sickness","volume":"2011","author":"Spinks","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/qjmed\/hcn153","article-title":"Promethazine overdose: Clinical effects, predicting delirium and the effect of charcoal","volume":"102","author":"Page","year":"2009","journal-title":"Qjm"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2174\/1389200033489523","article-title":"Classic histamine H1 receptor antagonists: A critical review of their metabolic and pharmacokinetic fate from a bird\u2019s eye view","volume":"4","author":"Sharma","year":"2003","journal-title":"Curr. Drug Metab."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/phar.1396","article-title":"Management of extravasation injuries: A focused evaluation of noncytotoxic medications","volume":"34","author":"Reynolds","year":"2014","journal-title":"Pharmacotherapy"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00003465-200405000-00009","article-title":"Innovative solutions in critical care units: Extravasation guidelines","volume":"23","author":"Hurst","year":"2004","journal-title":"Dimens. Crit. Care Nurs."},{"key":"ref_125","first-page":"1213","article-title":"Motion sickness: Advances in pathogenesis, prediction, prevention, and treatment","volume":"77","author":"Shupak","year":"2006","journal-title":"Aviat. Space. Environ. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults","volume":"67","author":"Fick","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1056\/NEJM200506233522522","article-title":"Boxed Warning Added to Promethazine Labeling for Pediatric Use","volume":"352","author":"Starke","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_128","unstructured":"Southard, B.T., and Khalili, Y. (2022, March 01). Al Promethazine, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK544361\/."},{"key":"ref_129","unstructured":"AIFA (2021). Riassunto Delle Caratteristiche del Prodotto-Prometazina, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Haress, N.G. (2015). Cinnarizine: Comprehensive Profile, Elsevier Inc.. [1st ed.].","DOI":"10.1016\/bs.podrm.2015.01.001"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.0000000000008105","article-title":"Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"93","author":"Oskoui","year":"2019","journal-title":"Neurology"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1186\/2193-1801-3-231","article-title":"Cinnarizine for the prophylaxis of migraine associated vertigo: A retrospective study","volume":"3","author":"Taghdiri","year":"2014","journal-title":"Springerplus"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.pediatrneurol.2014.05.031","article-title":"Efficacy and safety of cinnarizine in the prophylaxis of migraine in children: A double-blind placebo-controlled randomized trial","volume":"51","author":"Ashrafi","year":"2014","journal-title":"Pediatr. Neurol."},{"key":"ref_134","first-page":"597","article-title":"A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness","volume":"65","author":"Pingree","year":"1994","journal-title":"Aviat. Space. Environ. Med."},{"key":"ref_135","first-page":"160","article-title":"The prophylaxis of seasickness. A comparison of cinnarizine with hyoscine","volume":"226","author":"Hargreaves","year":"1982","journal-title":"Practitioner"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2165\/00023210-199912050-00004","article-title":"Prevention and treatment of motion sickness","volume":"12","author":"Gordon","year":"1999","journal-title":"CNS Drugs"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1185\/03007998309109781","article-title":"Cinnarizine in the prophylaxis of car sickness in children","volume":"8","author":"Macnair","year":"1983","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003495-198427010-00002","article-title":"Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use","volume":"27","author":"Holmes","year":"1984","journal-title":"Drugs"},{"key":"ref_139","first-page":"45","article-title":"Calcium antagonists in the prevention of motion sickness","volume":"57","author":"Lee","year":"1986","journal-title":"Aviat. Space. Environ. Med."},{"key":"ref_140","unstructured":"AIFA (2016). Riassunto Delle Caratteristiche Del Prodotto-Scopolamina Bromidrato, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2019-9-4","article-title":"Motion sickness: An overview","volume":"8","author":"Leung","year":"2019","journal-title":"Drugs Context"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Plescia, F., Salvago, P., Dispenza, F., Messina, G., Cannizzaro, E., and Martines, F. (2021). Efficacy and Pharmacological Appropriateness of Cinnarizine and Dimenhydrinate in the Treatment of Vertigo and Related Symptoms. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18094787"},{"key":"ref_143","unstructured":"(2022, March 01). National Institutes of Health Dimenhydrinate Injection, Solution-Label, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=bc71539e-1a33-4709-8a24-c2894e8dbc1c."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1210\/me.2004-0046","article-title":"Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR","volume":"18","author":"Huang","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"ref_145","unstructured":"(2022, March 01). National Institutes of Health Meclizine-Label, Available online: https:\/\/www.dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7575b02e-2659-4fc1-9fba-f2db53c09cd1."},{"key":"ref_146","unstructured":"(2022, March 01). National Institutes of Health Meclizine-Label, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b13cb390-20ed-43ce-aa74-5a754539f6e2."},{"key":"ref_147","unstructured":"(2022, March 01). National Institutes of Health MECLIZINE HCL 12.5 MG Tablet-Label, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=76efad7e-e765-430f-9232-63553d02f2c5."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3810\/pgm.2004.10.1605","article-title":"Patient notes: Motion sickness","volume":"116","author":"Setness","year":"2004","journal-title":"Postgrad. Med."},{"key":"ref_149","unstructured":"(2022, March 01). National Institutes of Health Promethazine-Label, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=51e3baab-eba7-460c-9de1-bf6cfc378310."},{"key":"ref_150","unstructured":"AIFA (2018). Riassunto Delle Caratteristiche Del Prodotto-Cinnarizina, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_151","unstructured":"FDA (2007). Cyproheptadine Hydrochloride Leaflet Cyproheptadine Hydrochloride Tablets Usp, FDA."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s00467-016-3334-4","article-title":"Diuretics in the treatment of hypertension","volume":"31","author":"Blowey","year":"2016","journal-title":"Pediatr. Nephrol."},{"key":"ref_153","unstructured":"AIFA (2019). Riassunto Delle Caratteristiche del Prodotto-Aldactone, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_154","unstructured":"EMA (2021). European Medicines Agency Plenadren-Summary of Product Characteristics, EMA."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa033280","article-title":"Methylprednisolone, Valacyclovir, or the Combination for Vestibular Neuritis","volume":"351","author":"Strupp","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_156","unstructured":"(2021, November 15). Up to Date-Methylprednisolone Pediatric Age. Available online: https:\/\/www.uptodate.com\/contents\/methylprednisolone-pediatric-drug-information."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: Mechanisms of Action in Health and Disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_158","unstructured":"AIFA (2021). Riassunto Delle Caratteristiche Del Prodotto-Medrol, AIFA (Agenzia Italiana del Farmaco)."},{"key":"ref_159","unstructured":"(2022, March 01). National Institutes of Health Ondansetron-Label, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=97c00a1d-1ac5-4eae-ad65-71ff5b1413e4."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMcp021154","article-title":"Vestibular neuritis","volume":"348","author":"Baloh","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_161","unstructured":"(2021, November 14). NIH Prochlorperazine Maleate Tablet, Film Coated-Label, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6b0e958b-fde0-74ea-b196-1e62f90b5bbe."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/9\/5\/584\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:57:34Z","timestamp":1760137054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/9\/5\/584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":161,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["children9050584"],"URL":"https:\/\/doi.org\/10.3390\/children9050584","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]}}}